Idorsia (XSWX:IDIA) Other Current Liabilities: CHF117.4 Mil (As of Mar. 2026)


XSWX:IDIA Idorsia Ltd XSWX:IDIA
48 GF Score
Price CHF6.40
GF Value CHF2.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Other Current Liabilities?

Idorsia XSWX:IDIA -3.18% 48 Other Current Liabilities is CHF117.4 Mil as of Mar. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.87 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Idorsia's other current liabilities for the quarter that ended in Mar. 2026 was CHF117.4 Mil.

Idorsia's quarterly other current liabilities increased from Sep. 2025 (CHF112.3 Mil) to Dec. 2025 (CHF123.3 Mil) but then declined from Dec. 2025 (CHF123.3 Mil) to Mar. 2026 (CHF117.4 Mil).

Idorsia's annual other current liabilities increased from Dec. 2023 (CHF69.1 Mil) to Dec. 2024 (CHF192.5 Mil) but then declined from Dec. 2024 (CHF192.5 Mil) to Dec. 2025 (CHF123.3 Mil).

Idorsia Other Current Liabilities Related Terms

Idorsia Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Idorsia's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia Other Current Liabilities Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.09 129.89 69.08 192.52 123.30

Idorsia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.35 106.46 112.31 123.30 117.36
XSWX:IDIA
48GF Score
Idorsia Ltd XSWX:IDIA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idorsia Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of CHF117.4 Mil mean?
Idorsia (XSWX:IDIA) has a Other Current Liabilities of CHF117.4 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Idorsia.
Is Idorsia's Other Current Liabilities too high?
Idorsia's current Other Current Liabilities is CHF117.4 Mil. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Other Current Liabilities compare to VRTX and REGN?
Idorsia's Other Current Liabilities of CHF117.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Idorsia. Idorsia's current Other Current Liabilities is CHF117.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.87, compared to a current price of CHF6.40 — trading 122.8% above its estimated fair value. The current Other Current Liabilities is CHF117.4 Mil. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Other Current Liabilities is CHF117.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Idorsia (XSWX:IDIA) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.40 is trading 122.8% above its estimated GF Value™ of CHF2.87. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for XSWX:IDIA:

  • Other Current Liabilities: CHF117.4 Mil
  • GF Value™: CHF2.87 vs. price of CHF6.40 (122.8% above fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score

Get the complete analysis for XSWX:IDIA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.40
Price
CHF2.87
GF Value